The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis

American Journal of Gastroenterology

Volumn 102, Issue 11, 2007, Pages 2387-2394

  Sheu, Bor Shyang ^a   Cheng, Hsiu Chi ^a   Chang, Wei Lun ^a   Chen, Wei Ying ^a   Kao, Ai Wen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ESOPHAGUS PH; FEMALE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS, PEPTIC; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 35448964191     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01468.x     Document Type: Article

References (24)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002 16 : 167 80.
2. Bixquert M. Maintenance therapy in gastro-oesophageal reflux disease. Drugs 2005 65 (Suppl 1 59 66.
3. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999 159 : 649 57.
4. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997 112 : 1798 810.
5. Spechler SJ. Epidemiology and natural history of gastroesophageal reflux disease. Digestion 1992 51 (Suppl 4 3s 7s.
6. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998 56 : 307 35.
7. Holloway RH, Dent J, Narielvala F, et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux esophagitis. Gut 1996 38 : 649 54.
8. Tytgat GN. Long-term therapy for refluxive esophagitis. N Engl J Med 1995 333 : 1148 50.
9. Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999 44 : S1 16.
10. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45 : 172 80.
11. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999 13 : 907 14.
12. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of "on-demand" therapy for 6 months. Aliment Pharmacol Ther 2001 15 : 347 54.
13. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006 24 : 377 85.
14. El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005 100 : 1243 50.
15. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005 143 : 199 211.
16. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases esophageal acid exposure. Gut 2007 56 : 749 55.
17. Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol 2003 32 : 645 50.
18. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006 354 : 2340 8.
19. Jacobson BC, Schroy PC 3rd. The skinny on obesity and reflux. Gastroenterology 2006 130 : 1925 6.
20. Fennerty MB. Review article : Alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther 2005 22 (Suppl 3 39 44.
21. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease [Review]. Am J Gastroenterol 2003 98 (Suppl 3 S40 8.
22. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006 24 : 377 85.
23. Kao AW, Sheu BS, Sheu MJ, et al. On-demand therapy for Los Angeles grade A and B reflux esophagitis: Esomeprazole versus omeprazole. J Formosan Med Assoc 2003 102 : 607 12.
24. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998 33 : 1023 9.